Compare GBX & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GBX | EVO |
|---|---|---|
| Founded | 1974 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Railroads | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | N/A | 2021 |
| Metric | GBX | EVO |
|---|---|---|
| Price | $46.46 | $3.13 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $50.67 | $7.00 |
| AVG Volume (30 Days) | ★ 334.5K | 269.8K |
| Earning Date | 01-08-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.75% | N/A |
| EPS Growth | ★ 27.96 | N/A |
| EPS | ★ 6.35 | N/A |
| Revenue | ★ $3,240,200,000.00 | $887,396,457.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $8.80 |
| P/E Ratio | $7.33 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $37.77 | $2.84 |
| 52 Week High | $71.06 | $5.10 |
| Indicator | GBX | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 58.21 | 50.69 |
| Support Level | $46.02 | $2.87 |
| Resistance Level | $47.03 | $3.05 |
| Average True Range (ATR) | 1.02 | 0.10 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 41.90 | 72.97 |
Greenbrier Companies Inc supplies equipment and services to international freight transportation markets, designing and marketing freight railcars in North America, Europe, and Brazil through subsidiaries and joint ventures. It provides railcar wheel services, parts, maintenance, and conversion services in North America. The company owns a lease fleet sourced mainly from its manufacturing operations and offers railcar management, regulatory compliance, and leasing services to railroads and owners. It operates two segments: Manufacturing and Leasing & Fleet Management, with the majority of revenue from Manufacturing. The company operates in the U.S. and internationally, with the majority of revenue from the U.S. market.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.